For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Investing.com -- A senior scientist at the U.S. Centers for Disease Control and Prevention (CDC) resigned Monday, expressing concerns about how COVID-19 and RSV hospitalization data would be used by ...

Fiona Havers, who oversees CDC respiratory virus data, told colleagues she no longer had confidence the data would be used ...

A Seattle infectious disease doctor, whose work was pivotal early in the COVID pandemic, shares more on her experience with ...

A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

Tourists in Israel and Lebanon have found themselves stranded at airports amid Israel's conflict with Iran. Fiona Jones ...

Secretary of Health and Human Services Robert F. Kennedy Jr.’s decision to fire the Centers for Disease Control and ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

Secretary of Health and Human Services Robert F. Kennedy Jr. made several false claims about vaccines in a Thursday ...

Kennedy Jr. accepted his new position as health secretary, he made a big show of distancing himself from his past life. Ne ...